Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized Study of Abiraterone Acetate, Enzalutamide or Apalutamide as First Line Therapy in Veterans With Castrate-sensitive Prostate Cancer

NCT05422911 is registered in ClinicalTrials.gov with Sun Pharmaceutical Industries Limited as lead sponsor.

NCT NCT05422911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05422911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized Study of Abiraterone Acetate, Enzalutamide or Apalutamide as First Line Therapy in Veterans With Castrate-sensitive Prostate Cancer
Lead sponsor
Sun Pharmaceutical Industries Limited
Phase
Phase 2
Overall status
Recruiting
Start date
August 31, 2022
Completion date
December 31, 2027
Enrollment
192 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

castrate-sensitive, castrate-sensitive prostate cancer, metastatic cancer, neoplasm, prostate